



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**


Applicant : Ishii et al.  
App. No : 10/551,488  
Filed : September 29, 2005  
For : MODIFIED THIOREDOXIN  
Examiner : Unknown  
Art Unit : 1632

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 18, 2006

(Date)


  
Eric Ives, Reg. No. 50,928


**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 11 references.
  - (X) Enclosing 11 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Eric Ives  
Registration No. 50,928  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



## INFORMATION DISCLOSURE STATEMENT

Applicant : Ishii et al.  
App. No : 10/551,488  
Filed : September 29, 2005  
For : MODIFIED THIOREDOXIN  
Examiner : Unknown  
Art Unit : 1632

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 11 references to be considered by the Examiner. Also enclosed are 11 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement. Please note the relevance of Japanese language references JP 10-191977 A and JP 05-507209 A is that they are cited in the International Search Report from PCT priority application serial no. PCT/JP2004/004523.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 1-13-06

By:   
Eric Ives  
Registration No. 50,928  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/551,488  
 Filing Date September 29, 2005  
 First Named Inventor Ishii, Yasuyuki  
 Art Unit 1632  
 Examiner Unknown  
 Attorney Docket No. SAEG129.015APC

(Multiple sheets used when necessary)

SHEET 1 OF 1

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 2004/013283 A2	02-12-2004	Univ. of Rochester		
	2	JP 10-191977	07-28-1998			
	3	EP 0 853 088 A2	07-15-1998	Oriental Yeast Co., Ltd.		
	4	JP 5-507209	10-21-1993			
	5	WO 92/13955	08-20-1992	Genetics Institute Inc.		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	6	OBLONG, J.E. et al. (1994) "Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin" <i>The Journal of Biological Chemistry</i> 269:11714-11720.	
	7	TONISSEN, K. et al. (1993) "Site-directed mutagenesis of human thioredoxin" <i>The Journal of Biological Chemistry</i> 268:22485-22489.	
	8	KIRKPATRICK, D.L. et al. (1998) "Mechanisms of inhibition of the thioredoxin growth factor system by Antitumor 2-imidazolyl disulfides" <i>Biochemical Pharmacology</i> 55:987-994.	
	9	GALLEGOS, A. et al. (1996) "Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells" <i>Cancer Research</i> 56:5765-5770.	
	10	NAKAMURA, H. et al. (1997) "Redox regulation of cellular activation" <i>Annu. Rev. Immunol.</i> 15:351-369.	
	11	HIROTA, K. et al. (1997) "AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1" <i>PNAS USA</i> 94:3633-3638.	

2260266:vr  
010406

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.